Target Healthcare REIT Ltd (THRL) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Target Healthcare REIT Ltd stock £1.75, price £1.20, upside +45.8%, quality 57 out of 100. Rating: undervalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range £0.5298 – £1.21 · fair‑value band £1.07 – £3.42 · the £1.20 price screens below the £1.75 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Target Healthcare REIT in your weekly email
Every Wednesday you see whether Target Healthcare REIT is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Target Healthcare REIT PLC is an externally managed FTSE 250 Real Estate Investment Trust. The firm provides shareholders with an attractive level of income, together with the potential for capital and income growth, from investing in a diversified portfolio of modern, purpose-built care homes.
Show moreShow less
The Group portfolio at 31 December 2025 comprised 86 assets let to 32 tenants with a total value of 894.6 million pounds. The Group invests in modern, purpose-built care homes that are let to high quality tenants who demonstrate strong operational capabilities and a strong care ethos.
The Group builds collaborative, supportive relationships with each of its tenants as it believes working in this way helps raise standards of care and helps its tenants build sustainable businesses. In turn, that helps the Group deliver stable returns to its investors.
Target Healthcare REIT PLC was incorporated in 2013 in United Kingdom.
Stock analysis
Target Healthcare REIT Ltd (THRL) currently trades at £1.20, while our model-based Fair Value estimate is £1.75, implying the stock looks roughly 31% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of £1.75 per share, and 10 of the 16 models we run sit above the £1.20 price.
Bear case: the Asset-Based group reads lowest at £0.7900, and 6 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: £1.07 (bear) to £3.42 (bull), the price of £1.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Real Estate sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Target Healthcare REIT Ltd reported revenue of £72.1M in FY2026 versus £55.5M in FY2022, a compound +6.7%/yr. Reported net income was £82.6M in FY2026, compounding +13.9%/yr from FY2022.
Key figures
Market cap £744M Small · P/E ratio 9.2 · P/S ratio 9.98 · EPS (TTM) £0.1300 · Dividend yield 5.0% · Net margin 104% · Return on equity 10.8% · Return on assets (EBIT) 4.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 49 out of 100 (low confidence).
What moves the price
The share trades about 1% below its 52-week high and 35% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Real Estate peers we cover trades at −19% fair-value upside, at 46%, THRL screens cheaper than that median.
Fair Value models
Bear£1.07Fair Value £1.75Bull£3.42
Price £1.20 · Upside +45.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then (£0.0251 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.51/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2021 (pandemic). Over 10 years: +15.6% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+15.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.2%
Dividend (yield on the price)5.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.10.2% vs 5.8%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.89% → 85%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+2.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +8.2% a year for the price and +0.0% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (14 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare Target Healthcare REIT Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.REIT - Healthcare Facilities · 25 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Target Healthcare REIT Ltd (THRL) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of £1.75 versus a price of £1.20, about +46% upside (undervalued).
What is the fair value of THRL?
Our model-based fair value for Target Healthcare REIT Ltd is £1.75 (as of Nov 8, 2026), built from audited fundamentals. The current price: £1.20.
What is the quality score of THRL?
Target Healthcare REIT Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Target Healthcare REIT Ltd (THRL)?
Our model-based price target is the fair value of £1.75 (as of Nov 8, 2026) from 16 valuation models. Cautious scenario £1.07, optimistic scenario £3.42. It is a calculation from audited fundamentals, not an analyst target.
What is the Target Healthcare REIT Ltd stock forecast for 2026?
Our models put fair value at £1.75, about +46% upside versus a price of £1.20 (undervalued). Cautious scenario £1.07, optimistic scenario £3.42. The calculation is refreshed regularly with new filings.
What is the revenue of Target Healthcare REIT Ltd (THRL)?
Target Healthcare REIT Ltd reported trailing-twelve-month revenue of about £74.6M (latest available figure, as of Nov 8, 2026).
Does Target Healthcare REIT Ltd pay a dividend?
Target Healthcare REIT Ltd currently shows a dividend yield of 5.00% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Target Healthcare REIT Ltd (THRL) and when is the ex-dividend date?
Target Healthcare REIT Ltd pays a dividend of £0.06 per share a year, a dividend yield of 5.0%. The last ex-dividend date was Aug 13, 2026. A dividend has been paid every year since at least 2013. The payout ratio is 46.2% of earnings. Free cash flow covers the dividend 1.20 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Target Healthcare REIT Ltd (THRL)?
For today's price to be fair in a discounted-cash-flow model, Target Healthcare REIT Ltd would have to grow free cash flow by +10.7 % per year for five years (discount rate 10.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of THRL use?
Our models discount Target Healthcare REIT Ltd at 10.5 %: a base by market capitalisation (small), damped by beta 0.55, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Target Healthcare REIT Ltd that is +10.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.5 %) and the same formula as our fair value.
How much growth has Target Healthcare REIT Ltd (THRL) delivered so far?
Over the past 5 years revenue at Target Healthcare REIT Ltd grew +7.9 % a year. The price currently implies free-cash-flow growth of +10.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Target Healthcare REIT Ltd (THRL) growing?
The median revenue growth in the sector is +2.7 % a year. That is the yardstick for the growth priced into Target Healthcare REIT Ltd (+10.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Target Healthcare REIT Ltd (THRL)?
The free-cash-flow yield on the price is 6.01 %: that much free cash flow Target Healthcare REIT Ltd produces per unit of market value. When it exceeds the discount rate of our models (10.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Target Healthcare REIT Ltd (THRL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Target Healthcare REIT Ltd it is £1.75 per share (as of Nov 8, 2026), against a price of £1.20. It is the blended result of 16 valuation models in 6 families (DCF Models, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Target Healthcare REIT Ltd stock overvalued or undervalued in 2026?
As of Nov 8, 2026, THRL trades below its calculated fair value: price £1.20, fair value £1.75, a gap of about +46% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of THRL?
No. The price is what the market pays today (£1.20); the fair value is what the company's own numbers justify (£1.75). For Target Healthcare REIT Ltd the two are £0.5500 per share apart. That gap is exactly why we show both numbers side by side.
How much is Target Healthcare REIT Ltd worth?
The market values Target Healthcare REIT Ltd at about £744M (market capitalisation, as of Nov 8, 2026). Per share that is £1.20; our models calculate a fair value of £1.75 per share.
What do the bullish and bearish scenarios say about THRL?
Our models span a range for Target Healthcare REIT Ltd: cautious scenario £1.07, base £1.75, optimistic £3.42 per share (as of Nov 8, 2026, price £1.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of THRL?
Target Healthcare REIT Ltd trades at a price-to-earnings ratio of 9.2 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of £1.75 is built from several models across several years. Other multiples: P/B 1.0, P/S 10.0, EV/EBITDA 8.7.
How solid is the balance sheet of Target Healthcare REIT Ltd (THRL)?
Balance-sheet figures for Target Healthcare REIT Ltd (as of Nov 8, 2026): return on equity 10.8%, debt of 0.14 per unit of equity. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is THRL from its 52-week high?
Target Healthcare REIT Ltd trades at £1.20, about 1% below its 52-week high of £1.21 and 35% above the low of £0.8898 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of £1.75 is for.
Which stocks are comparable to Target Healthcare REIT Ltd?
From the same area (Real Estate) we also value Welltower Inc, Ventas, Inc, Omega Healthcare Investors, Inc, Healthpeak Properties, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Target Healthcare REIT Ltd stock attractive at the current price?
The data as of Nov 8, 2026: price £1.20, calculated fair value £1.75 (+46%), Quality Score 57/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of THRL calculated?
We run Target Healthcare REIT Ltd through 16 models from 6 families: DCF Models, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of £1.75 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Target Healthcare REIT Ltd currently trades 31% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Target Healthcare REIT Ltd (THRL)?
The closing price on Nov 6, 2026 was £1.20. Our model-based fair value is £1.75, about +46% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Target Healthcare REIT Ltd right now?
The model range is unusually wide (£1.07 to £3.42). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality. As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Key figures of Target Healthcare REIT Ltd
How large is the market capitalisation of Target Healthcare REIT Ltd (THRL)?
The market capitalisation of Target Healthcare REIT Ltd is £744M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Target Healthcare REIT Ltd (THRL)?
The price-to-sales ratio of Target Healthcare REIT Ltd is 9.98 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Target Healthcare REIT Ltd (THRL)?
Earnings per share at Target Healthcare REIT Ltd are £0.1300 (price ÷ EPS = P/E 9.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Target Healthcare REIT Ltd (THRL)?
The dividend yield of Target Healthcare REIT Ltd is 5.0% (payout 46.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Target Healthcare REIT Ltd (THRL)?
The net margin of Target Healthcare REIT Ltd is 104% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Target Healthcare REIT Ltd (THRL)?
The return on equity (ROE) of Target Healthcare REIT Ltd is 10.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Target Healthcare REIT Ltd (THRL)?
On an EBIT basis the return on assets of Target Healthcare REIT Ltd is 4.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Target Healthcare REIT Ltd (THRL)?
The operating margin of Target Healthcare REIT Ltd is 87.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Target Healthcare REIT Ltd (THRL)?
Revenue at Target Healthcare REIT Ltd is growing +4.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Target Healthcare REIT Ltd (THRL)?
Earnings per share at Target Healthcare REIT Ltd are growing +57.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Target Healthcare REIT Ltd (THRL) carry?
The net debt of Target Healthcare REIT Ltd is £147M (fiscal year 2026, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Target Healthcare REIT Ltd in the live analysis
One click puts Target Healthcare REIT Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026